Clinical Snapshot: CagriSema is an investigational once-weekly subcutaneous co-formulation combining cagrilintide (a long-acting non-selective amylin/calcitonin receptor agonist, 2.4 mg) and semaglutide (a long-acting GLP-1 receptor agonist, 2.4 mg). In a randomized 32-week Phase 2 trial in individuals with type 2 diabetes and obesity (Lancet 2023), CagriSema achieved an average 15.6% body weight reduction, significantly outperforming both cagrilintide alone (8.1%) and semaglutide alone (5.1%). Ongoing Phase 3 REDEFINE trials evaluate its potential to rival or exceed tirzepatide's 20%+ efficacy benchmarks.
Quick Summary
| Feature | Semaglutide (Monotherapy) | Cagrilintide (Monotherapy) | CagriSema (Co-Formulation) |
|---|---|---|---|
| Target Receptors | GLP-1R | CTR + RAMP1/2/3 (Amylin) | GLP-1R + Amylin/Calcitonin |
| Primary Site of Action | Hypothalamus, Hindbrain | Area postrema, NTS, VTA | Complementary central circuits |
| Phase 2 Weight Loss (32 Wks) | 5.1% (in T2D cohort) | 8.1% (in T2D cohort) | 15.6% (synergistic) |
| HbA1c Reduction | -1.8% | -0.9% | -2.2% |
| Administration | Once weekly subcutaneous | Once weekly subcutaneous | Single fixed-dose pen, once weekly |
| Clinical Stage | FDA-approved (Wegovy/Ozempic) | Phase 3 investigational | Phase 3 (REDEFINE 1, 2, 3) |
Dual-Pathway Mechanism: Amylin Plus GLP-1
Native amylin is a 37-amino acid neuroendocrine hormone co-secreted with insulin by pancreatic beta cells in response to nutrient intake. It binds to calcitonin receptor (CTR) core complexes modified by receptor activity-modifying proteins (RAMP1, RAMP2, or RAMP3) to signal satiety directly in the hindbrain area postrema and the nucleus of the solitary tract (NTS).
While GLP-1 receptor agonists primarily suppress hunger by acting on pro-opiomelanocortin (POMC) neurons and slowing gastric motility, amylin agonism acts through distinct, non-overlapping homeostatic and hedonic pathways:
- Gastric Emptying Deceleration: Amylin suppresses postprandial glucagon secretion and slows gastric emptying through vagal afferents, flattening postprandial glucose spikes without inducing hypoglycemia.
- Hedonic Food Intake Suppression: Amylin receptors expressed in the ventral tegmental area (VTA) and lateral hypothalamic area modulate dopaminergic reward pathways, blunting hedonic food cravings and reward-driven overeating.
- Synergistic Neurocircuit Activation: Preclinical neuroimaging demonstrates that co-stimulating GLP-1 and amylin receptors recruits a wider network of hindbrain and forebrain satiety neurons than maximal doses of either mono-agonist alone.
Cagrilintide is acylated with a fatty acid diacid moiety that enables non-covalent binding to human serum albumin, extending its biological half-life to approximately 7 to 8 days, matching the weekly pharmacokinetic profile of semaglutide.
Clinical Trial Evidence: Phase 2 and REDEFINE Program
The therapeutic rationale for CagriSema was validated in a landmark Phase 2 randomized, double-blind trial published in The Lancet (Frias et al., 2023; NCT04982562):
- Study Design: 92 adults with type 2 diabetes on metformin (baseline BMI ~36 kg/m²) were randomized to once-weekly CagriSema (cagrilintide 2.4 mg + semaglutide 2.4 mg), cagrilintide 2.4 mg alone, or semaglutide 2.4 mg alone for 32 weeks.
- Weight Loss Efficacy: Mean body weight decreased by 15.6% with CagriSema, compared to 8.1% with cagrilintide and 5.1% with semaglutide alone. Over 89% of CagriSema participants achieved ≥5% weight loss, and 71.4% achieved ≥10% weight loss.
- Glycemic Control: Mean HbA1c fell by 2.2 percentage points with CagriSema, compared to 1.8 points with semaglutide and 0.9 points with cagrilintide.
The Phase 3 REDEFINE Clinical Program
Novo Nordisk initiated the Phase 3 REDEFINE clinical development program to test CagriSema across broader non-diabetic and diabetic obesity populations:
- REDEFINE 1 (NCT05567796): 68-week trial in ~3,400 individuals with overweight or obesity without type 2 diabetes, evaluating CagriSema vs cagrilintide monotherapy, semaglutide monotherapy, and placebo.
- REDEFINE 2 (NCT05394519): 68-week trial in ~1,200 individuals with obesity and type 2 diabetes.
- REDEFINE 3 (NCT05669755): Cardiovascular outcomes trial (CVOT) assessing major adverse cardiovascular events (MACE) in high-risk patients.
CagriSema vs Tirzepatide: Pharmacological Comparison
With tirzepatide (Mounjaro/Zepbound) having established the dual GIP/GLP-1 standard with ~20.9% mean weight loss at 72 weeks in the SURMOUNT-1 trial, CagriSema represents the first multi-agonist targeting an entirely separate endocrine pathway (amylin) rather than an incretin pathway (GIP):
| Metric | CagriSema | Tirzepatide |
|---|---|---|
| Primary Receptors | GLP-1R + Amylin (CTR/RAMP) | GIPR + GLP-1R |
| Peak Mean Trial Weight Loss | 15.6% (at 32 wks, Phase 2 T2D) | 15.7% (at 40 wks, SURPASS-2 T2D) |
| Lean Mass Retention | Investigational (Phase 3 DEXA sub-studies) | ~75% fat mass / 25% lean mass |
| Nausea Incidence | ~30% to 40% (mild-to-moderate) | ~30% to 33% |
| Head-to-Head Trial | REDEFINE 4 (direct active-comparator trial) | Evaluated directly against CagriSema |
The upcoming results from REDEFINE 4 (NCT06131424)—a direct head-to-head trial comparing CagriSema against tirzepatide 15 mg—will definitively establish which dual-pathway approach produces superior metabolic efficacy.
Investigational Dosing and Titration Schedules
In the Phase 3 REDEFINE protocols, CagriSema is administered as a single pre-filled pen delivering equal escalated doses of cagrilintide and semaglutide once weekly:
- Weeks 1–4: 0.25 mg cagrilintide / 0.25 mg semaglutide weekly
- Weeks 5–8: 0.5 mg cagrilintide / 0.5 mg semaglutide weekly
- Weeks 9–12: 1.0 mg cagrilintide / 1.0 mg semaglutide weekly
- Weeks 13–16: 1.7 mg cagrilintide / 1.7 mg semaglutide weekly
- Week 17 and onward: 2.4 mg cagrilintide / 2.4 mg semaglutide maintenance dose weekly
Gradual 4-week step-wise titration is essential to mitigate transient gastrointestinal side effects caused by concurrent GLP-1 and amylin receptor activation.
Safety Profile and Tolerability
Phase 2 trial safety data demonstrated that the adverse event profile of CagriSema is primarily gastrointestinal, consistent with the GLP-1 and amylin drug classes:
- Nausea: Reported by ~36% of participants on CagriSema, compared to ~24% on semaglutide and ~20% on cagrilintide. Most events were mild to moderate, transient, and clustered during dose escalation steps.
- Constipation and Diarrhea: Reported in 15% to 20% of participants, manageable with dietary hydration and fiber adjustments.
- Hypoglycemia: No severe hypoglycemic episodes occurred when administered without concurrent sulfonylureas or exogenous insulin.
- Pancreatitis and Gallbladder Events: Rates were comparable to approved GLP-1 receptor agonists; patients with personal or family histories of medullary thyroid carcinoma or pancreatitis were excluded from trials.
Frequently Asked Questions
What is CagriSema? CagriSema is an investigational once-weekly subcutaneous co-formulation developed by Novo Nordisk that combines cagrilintide (a long-acting amylin receptor agonist) and semaglutide (a long-acting GLP-1 receptor agonist) in a single injection pen.
How much weight loss was observed with CagriSema in trials? In its 32-week Phase 2 trial in individuals with type 2 diabetes and obesity, CagriSema produced a 15.6% mean body weight reduction, compared to 5.1% for semaglutide 2.4 mg alone and 8.1% for cagrilintide 2.4 mg alone.
Is CagriSema FDA approved? No. As of 2026, CagriSema remains an investigational compound undergoing Phase 3 evaluation in the REDEFINE clinical trial program. It has not received marketing authorization from the FDA or EMA.
How does CagriSema differ from Tirzepatide (Mounjaro / Zepbound)? Tirzepatide is a single molecule that activates GIP and GLP-1 incretin receptors. CagriSema combines a GLP-1 agonist with an amylin analogue, activating both gastric motility and neuroendocrine satiety circuits through non-incretin calcitonin receptor pathways.
What are the most common side effects of CagriSema? The most frequent adverse reactions in clinical trials are gastrointestinal, including nausea, constipation, diarrhea, and vomiting, typically mild-to-moderate and diminishing after dose escalation.